Anthropic has acquired Mithril Medicine, gaining two muscular dystrophy research programs and integrating Mithril's founder, Cody Tranbarger, into its team. Mithril was a small biotech focused on rare muscular dystrophy treatments, and Anthropic's AI helped accelerate research, achieving promising results in mice within 18 months. Anthropic is collaborating with several drug-development firms and aims to start human clinical trials by late 2028 if progress continues. This acquisition strengthens Anthropic's position in AI-assisted drug discovery, especially in preclinical stages.
Anthropic's acquisition of Mithril Medicine provides context for readers interested in biotech developments. For readers following the broader market, here is Pluang's snapshot as of Oct 28, 2026 22:22 WIB: out of 50 major cryptocurrencies, 38 rose and 11 fell today. Balancer (BAL) rose 11.14% to Rp16.297, EOS (EOS.IO) increased 8.13% to Rp12.649, while Basic Attention Token (BAT) dropped 3.78% to Rp2.549 with a 93% buy order activity on Pluang.
On National First Responders Day, ADT celebrated local first responders and its monitoring professionals by unveiling a renovated monitoring center in Irving, Texas, part of a $2 million investment. The upgraded center features enhanced equipment and...
Presidio was named Enterprise Partner of the Year and Software and Services Partner of the Year for the Americas at the Cisco Partner Summit 2026. These awards recognize partners who excel in service and innovation, helping customers succeed through ...
Cobalt Boats unveiled the 2027 265 Coastal Edition, a fully redesigned luxury outboard runabout tailored for coastal boating enthusiasts. Featuring wood-free construction, enhanced comfort, and advanced technology like dual 9-inch displays and option...
Air Canada and CAE announced the opening of applications on November 1, 2026, for the 2027 Commandante-Judy-Cameron scholarships. These scholarships support up to eight Canadian women pursuing professional pilot or aircraft maintenance technician tra...
Arcutis Biotherapeutics has appointed Dr. Rob Scott, a seasoned pharmaceutical executive with over 40 years of experience, to its Board of Directors. Dr. Scott's expertise in developing and securing approvals for innovative medicines, including derma...
